May 28, 2026
142
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
1:06Now PlayingOriginally for blood sugar, GLP-1 drugs caused weight loss as a side effect. Manufacturers spun this, gaining FDA approval for weight loss, creating a trillion-dollar industry. Eli Lilly bypassed PBMs, selling directly to consumers and achieving massive success. #GLP1 #WeightLoss #Pharma #EliLilly #healthcareinnovation
Have you ever wondered how weight loss drugs like GLP-1s suddenly became a trillion-dollar industry? It is not just about the science but a massive shift in how these medications are marketed and sold directly to you.
🚀
In this video, we explore the fascinating business strategy behind the rise of modern weight loss medications. Originally developed to help manage blood sugar levels, these drugs had a side effect that changed everything: weight loss. Manufacturers recognized the opportunity, shifted the narrative, and successfully got these drugs approved specifically for weight management, sparking a massive industry boom.
💰
We take a deep dive into the specific case of Eli Lilly and their groundbreaking decision to bypass Pharmacy Benefit Managers, also known as PBMs. Traditionally, drug companies have to navigate complex rebate negotiations and access hurdles to reach patients through insurance networks. Eli Lilly chose a different path by selling directly to consumers, a move that contributed to their recent trillion-dollar valuation as a publicly traded company.
📈
This shift is more than just a corporate success story; it is a signal to the entire pharmaceutical industry. Other manufacturers are now looking at this direct-to-consumer model as a blueprint for the future. By cutting out the middleman, these companies are changing how we access healthcare and how the stock market views the value of medical innovation.
🔔
If you found this breakdown of the pharmaceutical industry and the business of GLP-1s insightful, please give this video a like and subscribe for more deep dives into healthcare and business strategy. What do you think about companies selling medications directly to patients? Share your thoughts in the comments below.
𝗔𝗯𝗼𝘂𝘁 𝗧𝗵𝗲 𝗖𝗵𝗮𝗻𝗻𝗲𝗹
𝗪𝗲𝗹𝗰𝗼𝗺𝗲 𝘁𝗼 𝗶𝗦𝗵𝗼𝗼𝗸—𝗪𝗵𝗲𝗿𝗲 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝗠𝗲𝗲𝘁𝘀 𝗜𝗻𝘀𝗶𝗴𝗵𝘁 & 𝗥𝗲𝗮𝗹-𝗪𝗼𝗿𝗹𝗱 𝗖𝗼𝗻𝗻𝗲𝗰𝘁𝗶𝗼𝗻𝘀.
At iShook, where digital finance, entrepreneurship, and cultural insight meet. Our channel is your gateway to understanding the future of money, business, and technology through expert interviews, insightful podcasts, and real-world applications.
🎙️ Tune into our flagship shows—iShook Daily and Midnight Market—for fresh perspectives on blockchain, e-commerce, investing, and digital innovation.
💡 Whether you're an entrepreneur, investor, or curious mind, iShook delivers valuable insights from industry leaders, creators, and innovators shaping the global digital economy.
🌐 Connect with our growing digital community at iShook.me, and explore the frontier of blockchain-powered content on iShook.io.
Subscribe now to stay informed, inspired, and empowered to navigate and lead in today’s fast-changing digital world.
🔗𝗘𝘅𝗽𝗹𝗼𝗿𝗲 𝗶𝗦𝗵𝗼𝗼𝗸 𝗮𝗻𝗱 𝗢𝘂𝗿 𝗣𝗹𝗮𝘁𝗳𝗼𝗿𝗺𝘀
Download the Cliqtok App
iShook Official Website
Learn More About Usits ishook.me
📲 𝗙𝗼𝗹𝗹𝗼𝘄 𝗶𝗦𝗵𝗼𝗼𝗸 𝗼𝗻 𝗦𝗼𝗰𝗶𝗮𝗹 𝗠𝗲𝗱𝗶𝗮
LinkedIn: / ishook
Facebook: / ishookco
Twitter/Xits
Instagram: / ishook411
𝗧𝗵𝗮𝗻𝗸𝘀 𝗙𝗼𝗿 𝗪𝗮𝘁𝗰𝗵𝗶𝗻𝗴: How Weight Loss Drugs Changed the Pharma Industry
:#GLP1 #EliLilly #WeightLossDrugs #HealthcareBusiness #StockMarket
𝗥𝗲𝗹𝗮𝘁𝗲𝗱 𝗦𝗲𝗮𝗿𝗰𝗵𝗲𝘀
healthcare economics
pharma companies
healthcare reform
medical business
prescription drug market
health innovation
pharmaceutical trends
youtube shorts healthcare
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.